



Evaluation of the safety and efficacy of transcatheter aortic valve implantation in patients with a severe stenotic bicuspid aortic valve in a Chinese population*

Xian-bao LIU¹, Ju-bo JIANG¹, Qi-jing ZHOU², Zhao-xia PU³, Wei HE⁴, Ai-qiang DONG⁵, Yan FENG¹, Jun JIANG¹, Yong SUN¹, Mei-xiang XIANG¹, Yu-xin HE¹, You-qi FAN¹, Liang DONG¹, Jian-an WANG^{†‡1}

(¹Cardiovascular Key Lab of Zhejiang Province, Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)

(²Department of Radiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)

(³Department of Echocardiography, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)

(⁴Department of Anesthesiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)

(⁵Department of Cardiosurgery, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China)

[†]E-mail: jian_an_wang@yahoo.com

Received Jan. 21, 2015; Revision accepted Feb. 23, 2015; Crosschecked Feb. 26, 2015

Abstract: Objective: The purpose of this study is to evaluate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with a severe stenotic bicuspid aortic valve (BAV) in a Chinese population. While several groups have reported the feasibility, efficacy, and safety of TAVI for patients with a BAV, worldwide experience of the technique is still limited, especially in China. Methods: From March 2013 to November 2014, high surgical risk or inoperable patients with symptomatic severe aortic stenosis (AS) who had undergone TAVI at our institution were selected for inclusion in our study. Results were compared between a BAV group and a tricuspid aortic valve (TAV) group. Results: Forty patients were included in this study, 15 (37.5%) of whom were identified as having a BAV. In the BAV group, the aortic valve area was smaller ((0.47±0.13) vs. (0.59±0.14) cm²), the ascending aortic diameter was larger ((40.4±4.4) vs. (36.4±4.3) mm), and the concomitant aortic regurgitation was lower. No significant differences were found between the groups in the other baseline characteristics. No differences were observed either in the choice of access or valve size. The procedural success achieved in this study was 100%. There were no differences between groups in device success (86.7% vs. 88.0%), 30-d mortality (6.7% vs. 8.0%), or 30-d combined end point (13.3% vs. 12.0%). The incidences of new pacemaker implantation, paravalvular regurgitation and other complications, recovery of left ventricle ejection fraction and heart function were similar in both groups. Conclusions: Patients with a severely stenotic BAV can be treated with TAVI, and their condition after treatment should be similar to that of people with a TAV.

Key words: Aortic valve stenosis, Bicuspid aortic valve, Transcatheter aortic valve implantation

doi:10.1631/jzus.B1500017

Document code: A

CLC number: R542.5

1 Introduction

Transcatheter aortic valve implantation (TAVI) has emerged as a promising treatment strategy for patients with severe symptomatic aortic stenosis (AS), whose condition has been carefully evaluated as being high surgical risk or inoperable patients (Leon *et al.*,

[‡] Corresponding author

* Project supported by the Fundamental Research Funds from Zhejiang University (No. 2012FZA7008), China

ORCID: Xian-bao LIU, <http://orcid.org/0000-0002-2891-7019>; Jian-an WANG, <http://orcid.org/0000-0003-0409-8941>

© Zhejiang University and Springer-Verlag Berlin Heidelberg 2015

2010; Smith *et al.*, 2011; Adams *et al.*, 2014). Despite the great improvements achieved in recent years, unfortunately, TAVI for patients with a bicuspid aortic valve (BAV) is still deemed to be a relative contraindication because of the exclusion of these patients from most clinical trials (Leon *et al.*, 2010; Smith *et al.*, 2011). One possible concern is the unfavorable anatomy of a BAV, which will result in elliptical deployment of a bioprosthesis, increase the procedural complications including residual aortic regurgitation, coronary obstruction, annulus rupture and aortic dissection, and decrease the durability of the bioprosthesis (Zegdi *et al.*, 2008; 2010; Wijesinghe *et al.*, 2010; Himbert *et al.*, 2012). However, BAV is the most common congenital heart disease, occurring in 0.5% to 2.0% of the general population (Roberts, 1970; Nistri *et al.*, 2005; Tutar *et al.*, 2005), and has been observed in about 50% of aortic valves resected during surgical aortic valve replacement (SAVR) (Roberts and Ko, 2005). Although several groups have reported the feasibility, efficacy, and safety of TAVI for patients with a BAV (Wijesinghe *et al.*, 2010; Himbert *et al.*, 2012; Hayashida *et al.*, 2013; Bauer *et al.*, 2014; Costopoulos *et al.*, 2014; Kochman *et al.*, 2014), global experience of the procedure is lacking, especially in China.

The purpose of this study is to evaluate the safety and efficacy of TAVI in patients with a severe stenotic BAV in a Chinese population.

2 Subjects and methods

From March 2013, consecutive patients with symptomatic severe AS (valve area $<1.0 \text{ cm}^2$), who had undergone TAVI at our institution, were prospectively included in this study. The inclusion criteria for candidates with TAVI included surgical high risk defined as logistic EuroSCORE $\geq 20\%$, or other risk factors not included in the risk scores (e.g. frailty, porcelain aorta, previous chest radiotherapy, and advanced age). The decision to proceed with TAVI was reviewed by a dedicated heart valve team, including experienced interventional cardiologists, general cardiologists, cardiac surgeons, anesthesiologists, and cardiac radiologists. Between March 2013 and November 2014, a total of 40 patients underwent TAVI, 15 (37.5%) of whom had a BAV.

According to a previous report (Hayashida *et al.*, 2013), BAVs are defined as having deformed aortic valves with two functional cusps forming a valve mechanism with less than three zones of parallel apposition between the cusps. BAVs are classified into three types depending on the number of raphe: type 0, valves with no raphe; type 1, valves with one raphe; and type 2, valves with two raphe (Sievers and Schmidtke, 2007). Patients with functional BAVs due to commissural fusion in tricuspid aortic valves (TAVs) were not included in the BAV group. The diagnosis of BAV was made by imaging specialists through transthoracic echocardiography (TTE) and dual-source computed tomography (DSCT) in all cases.

As to procedure aspects, the selection of the transfemoral access or alternative approaches, including the subclavian artery and aorta, depended on the size, calcification, and tortuosity of the iliofemoral arterial access performed by a DSCT. The choices of general or local anesthesia, cutting down or puncture of vascular access were made according to each patient's condition and the operator's experience. Two valve prostheses, CoreValve (Medtronic Inc., Minneapolis, Minnesota, USA) in diameters of 23, 26, 29, and 31 mm and VENUS A (Venus Medtech, Hangzhou, China) in diameters of 23, 26, 29, and 32 mm, were used in this study. All patients received dual antiplatelet therapy daily before TAVI or were administered a loading dosage of 300 mg of clopidogrel and 300 mg of aspirin before the procedure. After the successful preparation of the vascular access, a bolus of intravenous heparin (70 IU/kg) was injected to achieve an activated clotting time of 250 to 300 s, which was checked and adjusted every 30 min thereafter. Clopidogrel at 75 mg/d was used for 3 to 6 months after the procedure and aspirin at 100 mg/d will be continued for life if there were no contraindications. Oral anticoagulation was administered if necessary. Follow-up data from all the patients were collected at 30 d, including clinical assessment, electrocardiography, and TTE data.

Clinical end points and device success were defined according to the standardized definitions for TAVI published by the Valve Academic Research Consortium (Leon *et al.*, 2011). The main end points derived from this study were the all-cause 30-d mortality, a 30-d safety composite end point, and device success. The combined 30-d safety end points included

all-cause mortality, major stroke, life-threatening bleeding, acute kidney injury stage 3 (including renal replacement therapy), periprocedural myocardial infarction, major vascular complications and repeated procedure for valve-related dysfunction (surgical or interventional therapy). Device success was defined as successful vascular access, delivery and deployment of a single prosthesis in the proper anatomical location, successful retrieval of the delivery system and intended performance of the prosthetic heart valve (aortic valve area $>1.2 \text{ cm}^2$ and mean aortic valve gradient $<20 \text{ mmHg}$ or peak velocity $<3 \text{ m/s}$,

without moderate or severe prosthetic valve aortic regurgitation) (Leon *et al.*, 2011).

Qualitative variables are expressed as numbers or percentages and quantitative variables as mean \pm standard deviation (SD). The unpaired Student's *t*-test or Wilcoxon rank-sum test was used to compare quantitative variables according to the variable's distribution. Qualitative variables were compared using the Fisher exact test. Statistical significance was defined as $P < 0.05$. The data were analyzed using SPSS statistics 21.0 (SPSS Inc., Chicago, Illinois, USA).

Table 1 Baseline characteristics of patients in this study

Characteristics	Total (<i>n</i> =40)	BAV (<i>n</i> =15)	TAV (<i>n</i> =25)	<i>P</i> -value
Age (year)	75.7 \pm 5.5	75.4 \pm 5.7	75.8 \pm 5.5	0.81
Men	26 (65.0%)	9 (60.0%)	17 (68.0%)	0.61
BMI (kg/m ²)	24.4 \pm 3.4	23.6 \pm 4.8	21.7 \pm 3.1	0.32
Hypertension	19 (47.5%)	5 (33.3%)	14 (56.0%)	0.17
Diabetes mellitus	3 (7.5%)	0 (0%)	3 (12.0%)	0.44
Coronary artery disease	12 (30.0%)	3 (20.0%)	9 (36.0%)	0.48
Previous MI	0 (0%)	0 (0%)	0 (0%)	1.00
Previous CABG	0 (0%)	0 (0%)	0 (0%)	1.00
Previous PCI	6 (15.0%)	3 (20.0%)	3 (12.0%)	0.82
Previous valve surgery	0 (0%)	0 (0%)	0 (0%)	1.00
Previous pacemaker/ICD implantation	0 (0%)	0 (0%)	0 (0%)	1.00
Cerebral vascular disease	2 (5.0%)	0 (0%)	2 (8.0%)	0.52
Peripheral vascular disease	6 (15.0%)	2 (13.3%)	4 (16.0%)	1.00
Atrial fibrillation	3 (7.5%)	1 (6.7%)	2 (8.0%)	1.00
COPD	8 (20.0%)	4 (26.7%)	4 (16.0%)	0.68
Chronic renal insufficiency (eGFR $<60 \text{ ml/min}$)	16 (40.0%)	4 (26.7%)	12 (48.0%)	0.18
Pulmonary hypertension (SPAP $>60 \text{ mmHg}$)	5 (12.5%)	2 (13.3%)	3 (12.0%)	1.00
Malignancy	4 (10.0%)	0 (0%)	4 (16.0%)	0.28
NYHA class III-IV	34 (85.0%)	13 (86.7%)	21 (84.0%)	1.00
Logistic EuroSCORE (%)	19.6 \pm 13.6	16.1 \pm 11.1	21.8 \pm 14.7	0.22
STS score (%)	7.1 \pm 5.2	5.6 \pm 4.1	7.5 \pm 5.9	0.18
LVEF (%)	51.0 \pm 12.5	51.1 \pm 12.6	51.0 \pm 12.7	0.90
LVEF $<40\%$	9 (22.5%)	3 (20.0%)	6 (24.0%)	1.00
Aortic-valve area (cm ²)	0.54 \pm 0.15	0.47 \pm 0.13	0.59 \pm 0.14	0.02
Aortic-valve gradient (mmHg)	58.0 \pm 16.8	64.1 \pm 19.5	54.3 \pm 14.2	0.08
Peak velocity (m/s)	4.9 \pm 0.7	5.1 \pm 0.8	4.9 \pm 0.6	0.29
AR (0-4)	2.2 \pm 0.8	1.8 \pm 0.9	2.4 \pm 0.7	0.01
AR >2	15 (37.5%)	2 (13.3%)	13 (52.0%)	0.01
Mitral regurgitation (0-4)	2.3 \pm 0.6	2.3 \pm 0.7	2.2 \pm 0.6	0.32
Mean annulus diameter, CT-measured (mm)	24.6 \pm 2.4	24.7 \pm 1.8	24.6 \pm 2.7	0.96
Short-axis annulus size, CT-measured (mm)	21.5 \pm 2.3	21.8 \pm 1.9	21.3 \pm 2.5	0.58
Long-axis annulus size, CT-measured (mm)	27.6 \pm 3.1	27.7 \pm 3.1	27.5 \pm 3.2	0.87
Ascending aorta diameter, CT-measured (mm)	37.9 \pm 4.7	40.4 \pm 4.4	36.4 \pm 4.3	0.01

Data are expressed as mean \pm SD or number (percentage), except *P*-values. BAV: bicuspid aortic valve; TAV: tricuspid aortic valve; BMI: body mass index; MI: myocardial infarction; CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; ICD: implantable cardioverter defibrillator; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; SPAP: systolic pulmonary artery pressure; NYHA: New York Heart Association; STS: Society of Thoracic Surgeons; LVEF: left ventricular ejective fraction; AR: aortic regurgitation

3 Results

From March 2013 to November 2014, a total of 40 patients with symptomatic severe AS undergoing TAVI were consecutively included in this study. Fifteen of these patients (37.5%) were identified as having a BAV by DSCT and TTE. The BAV group consisted of type 0 (11 cases) and type 1 (4 cases) according to previously described criteria (Sievers and Schmidtke, 2007). The aortic valve area was much smaller (0.47 ± 0.13) vs. (0.59 ± 0.14) cm^2 , $P=0.02$) and the mean gradient was higher (64.1 ± 19.5) vs. (54.3 ± 14.2) mmHg, $P=0.08$) in the BAV group, and concomitant aortic regurgitation occurred more often in the TAV group as shown by TTE (Table 1). The ascending aortic diameter was larger (40.4 ± 4.4) vs. (36.4 ± 4.3) mm, $P=0.01$) in the BAV group according to DSCT evaluation. No significant differences were found between the BAV and TAV groups in other baseline and clinical characteristics (Table 1).

CoreValve was implanted in 72.5% of cases and VENUS A in the rest. The transfemoral approach was used in 90% of cases, a subclavian approach in only one patient and direct aortic access in three patients. A 29-mm prosthesis was most frequently applied, whether CoreValve or VENUS A. However, no

difference was observed between the BAV and TAV groups in either the choice of access or the valve size (Table 2).

A procedural success rate of 100% was achieved in this study. Device success was 86.8% in the BAV group and 88.0% in the TAV group ($P=1.00$), and the incidence of second valve implantation was similar in each group. New pacemakers were implanted in 5 patients (12.5%), 2 from the BAV group (13.3%) and 3 from the TAV group (12.0%). No annulus rupture, coronary occlusion or conversion to open heart surgery occurred. There were no significant differences between the two groups in bleeding, cerebrovascular accidents, major vascular complications, or myocardial infarction after the procedure. No acute kidney injury or new onset atrial fibrillation was observed in either group (Table 3).

All patients were followed up for one month. There were no differences between the two groups in the incidence of 30-d mortality (6.7% vs. 8.0%, $P=1.00$) or 30-d combined safety end point (12.5% vs. 12.0%, $P=1.00$) (Table 3). Clinical follow-up showed that the heart function status in both groups had obviously improved, and heart function with NYHA III was found in only one patient with TAV anatomy. Echocardiography showed no differences in aortic

Table 2 Delivery access, type, and size of implanted valves

Variable	Case number*			P-value
	Total (n=40)	BAV (n=15)	TAV (n=25)	
Access				
CoreValve	29 (72.5%)	10 (66.7%)	19 (76.0%)	0.78
Transfemoral	27 (67.5%)	10 (66.7%)	17 (68.0%)	1.00
Transsubclavian	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
Transaortic	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
VANUS A	11 (27.5%)	5 (33.3%)	6 (24.0%)	0.78
Transfemoral	9 (22.5%)	3 (20.0%)	6 (24.0%)	1.00
Transsubclavian	0 (0%)	0 (0%)	0 (0%)	1.00
Transaortic	2 (5.0%)	2 (13.3%)	0 (0%)	0.14
Transfemoral access TOTAL	36 (90.0%)	13 (86.7%)	23 (92.0%)	1.00
Valve size				
CoreValve				
23 mm	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
26 mm	5 (12.5%)	1 (6.7%)	4 (16.0%)	0.71
29 mm	19 (47.5%)	9 (60.0%)	10 (40.0%)	0.22
31 mm	4 (10.0%)	0 (0%)	4 (16.0%)	0.28
VANUS A				
23 mm	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
26 mm	3 (7.5%)	2 (13.3%)	1 (4.0%)	0.64
29 mm	6 (15.0%)	3 (20.0%)	3 (12.0%)	0.82
32 mm	1 (2.5%)	0 (0%)	1 (4.0%)	1.00

* Data are expressed as number (percentage). BAV: bicuspid aortic valve; TAV: tricuspid aortic valve

valve area, mean gradient, peak velocity, or paravalvular regurgitation. No significant difference was observed in the amelioration of the left ventricular ejection fraction (LVEF), which increased from (51.1±12.6)% to (58.3±7.6)% in the BAV group and from (51.0±12.7)% to (57.4±6.9)% in the TAV group (Table 3).

4 Discussion

In this study, the characteristics and clinical outcomes of patients with severe symptomatic BAV who underwent TAVI, were compared to those with a TAV. We found that the incidences of 30-d mortality, 30-d combined safety end point, and device success

Table 3 Intraprocedural, postprocedural, and clinical outcomes

Variable	Total (n=40)	BAV (n=15)	TAV (n=25)	P-value
Intraprocedural				
Annulus rupture	0 (0%)	0 (0%)	0 (0%)	1.00
Coronary occlusion	0 (0%)	0 (0%)	0 (0%)	1.00
Conversion to open heart surgery	0 (0%)	0 (0%)	0 (0%)	1.00
Valve-in-valve	5 (12.5%)	2 (13.3%)	3 (12.0%)	1.00
Procedural success	40 (100%)	15 (100%)	25 (100%)	1.00
Device success	35 (87.5%)	13 (86.7%)	22 (88.0%)	1.00
Postprocedural				
Transfusions ≥4 U	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
Bleeding (life threatening)	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
Bleeding (major)	6 (15.0%)	1 (6.7%)	5 (20.0%)	0.49
Myocardial infarction	1 (2.5%)	1 (6.7%)	0 (0%)	0.38
Cerebrovascular accident				
TIA	0 (0%)	0 (0%)	0 (0%)	1.00
Stroke	2 (5.0%)	1 (6.7%)	1 (4.0%)	1.00
minor	2 (5.0%)	1 (6.7%)	1 (4.0%)	1.00
major	0 (0%)	0 (0%)	0 (0%)	1.00
Major vascular complications	1 (2.5%)	1 (6.7%)	0 (0%)	0.38
Acute kidney injury	0 (0%)	0 (0%)	0 (0%)	1.00
New pacemaker	5 (12.5%)	2 (13.3%)	3 (12.0%)	1.00
New onset atrial fibrillation	0 (0%)	0 (0%)	0 (0%)	1.00
Valve-related dysfunction requiring repeat procedure	0 (0%)	0 (0%)	0 (0%)	1.00
Aortic-valve area (cm ²)	1.58±0.30	1.55±0.15	1.61±0.35	0.49
Aortic-valve gradient (mmHg)	10.5±3.8	9.6±3.1	11.0±4.2	0.38
Peak velocity (m/s)	2.2±0.4	2.2±0.3	2.3±0.4	0.36
LVEF (%)	57.7±7.1	58.3±7.6	57.4±6.9	0.72
PVLR (0–4)	1.6±0.7	1.8±0.4	1.6±0.8	0.43
PVLR>2	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
MR (0–4)	1.9±0.7	2.1±0.5	1.9±0.8	0.23
MR>2	5 (12.5%)	2 (13.3%)	3 (12.0%)	1.00
NYHA III–IV	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
30-d mortality				
From any causes	3 (7.5%)	1 (6.7%)	2 (8.0%)	1.00
From cardiac causes	1 (2.5%)	0 (0%)	1 (4.0%)	1.00
30-d composite safety end point	5 (12.5%)	2 (13.3%)	3 (12.0%)	1.00

Data are expressed as mean±SD or number (percentage), except P-values. BAV: bicuspid aortic valve; TAV: tricuspid aortic valve; TIA: transient ischemic attack; LVEF: left ventricular ejective fraction; PVLR: paravalvular regurgitation; MR: mitral regurgitation; NYHA: New York Heart Association

of the BAV group were similar to those of the TAV group. The results of this study suggest that TAVI in high surgical risk or inoperable patients with severely stenotic BAV is safe and feasible.

Many studies and some case reports have demonstrated a positive effect of TAVI when used on BAV patients whose condition is inoperable or has a high surgical risk (Wijesinghe *et al.*, 2010; Himbert *et al.*, 2012; Hayashida *et al.*, 2013; Bauer *et al.*, 2014; Costopoulos *et al.*, 2014; Kochman *et al.*, 2014). However, experience from Asian populations, especially from China, is scarce. To our knowledge, this is the first report to compare TAVI in severe AS patients with a BAV versus those with a TAV in a Chinese population. In view of the good performance of the TAVI procedure in patients with a BAV, our results indicate that TAVI can be safely and effectively applied to BAV patients in Chinese populations.

Similar to previous studies of the use of TAVI on patients with a BAV, no increase in complications, such as residual aortic regurgitation, coronary obstruction, annulus rupture, or aortic dissection, was observed in our study. To achieve satisfactory results from the procedure, the selection of the access route according to the anatomy and angulation, choice of balloon size for pre-dilation and valve size, consideration of the implanting depth and whether post-dilation should be used, and how to do the post-dilation are very important. However, no ideal software for the TAVI procedure is available to guide the selection of an appropriate valve for individuals, especially for patients with a BAV. Thus, the experience of the heart valve team and careful discussion before the procedure are crucial to avoid complications during the procedure.

As noted, the proportion of patients with a BAV (15 of 40, 37.5%) in this study was much higher than those of previous studies in Europe (3.0% to 9.2%) (Himbert *et al.*, 2012; Hayashida *et al.*, 2013; Bauer *et al.*, 2014; Costopoulos *et al.*, 2014; Kochman *et al.*, 2014). This phenomenon has also been observed in almost every center that performs TAVI in China, and in some centers as many as 50% of the patients who underwent TAVI had a BAV. Although functional BAVs due to commissural fusion of TAVs may be included in estimates in some centers, the proportion of true BAVs is actually very high in China. In this study, the percentage of BAVs with type 0 was 73.3%.

However, epidemic data on the prevalence of BAVs show that the percentage of patients with a severely stenotic BAV among all patients with severe AS is very low. Therefore, further epidemic investigations in the field of AS in Chinese populations are urgently needed.

Aortic dilation is frequently associated with BAV, and surgery of the ascending aorta is indicated in cases of ascending aortic diameter >45 mm when SAVR is scheduled or ascending aortic diameter >50 mm in the presence of other risk factors (Erbel *et al.*, 2014). In our study, patients with ascending aortic diameter >50 mm were excluded. Only two patients with ascending aortic diameter >45 mm (48.4 and 49.4 mm, respectively) were included. However, the surgical risk evaluation suggested these two patients were at high risk and surgery was not recommended by our heart valve team. Thus, careful follow-up of all the patients with aortic dilation should be applied and surgery will be considered when the aortic diameter increased very quickly in accordance with the suggestions of the heart valve team.

Limitations of this study include the small sample size and the short-term of the follow-up. Furthermore, data from only single center were collected, making it difficult to generalize about the use of TAVI for treating BAV patients. Multi-center registries with large samples and long-term follow-up results will make the conclusion more convincing.

In conclusion, in Chinese populations, patients with a severely stenotic BAV can be treated with TAVI, and their condition after treatment should be similar to that of patients with a TAV.

Compliance with ethics guidelines

Xian-bao LIU, Ju-bo JIANG, Qi-jing ZHOU, Zhao-xia PU, Wei HE, Ai-qiang DONG, Yan FENG, Jun JIANG, Yong SUN, Mei-xiang XIANG, Yu-xin HE, You-qi FAN, Liang DONG, and Jian-an WANG declare that they have no conflict of interest.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study. Additional informed consent was obtained from all patients for whom identifying information is included in this article.

References

Adams, D.H., Popma, J.J., Reardon, M.J., 2014. Transcatheter

- aortic-valve replacement with a self-expanding prosthesis. *N. Engl. J. Med.*, **371**(10):967-968. [doi:10.1056/NEJMc1408396]
- Bauer, T., Linke, A., Sievert, H., et al., 2014. Comparison of the effectiveness of transcatheter aortic valve implantation in patients with stenotic bicuspid versus tricuspid aortic valves (from the German TAVI Registry). *Am. J. Cardiol.*, **113**(3):518-521. [doi:10.1016/j.amjcard.2013.10.023]
- Costopoulos, C., Latib, A., Maisano, F., et al., 2014. Comparison of results of transcatheter aortic valve implantation in patients with severely stenotic bicuspid versus tricuspid or nonbicuspid valves. *Am. J. Cardiol.*, **113**(8):1390-1393. [doi:10.1016/j.amjcard.2014.01.412]
- Erbel, R., Aboyans, V., Boileau, C., et al., 2014. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur. Heart J.*, **35**(41):2873-2926. [doi:10.1093/eurheartj/ehu281]
- Hayashida, K., Bouvier, E., Lefèvre, T., et al., 2013. Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. *Circ. Cardiovasc. Interv.*, **6**(3):284-291. [doi:10.1161/CIRCINTERVENTIONS.112.000084]
- Himbert, D., Pontnau, F., Messika-Zeitoun, D., et al., 2012. Feasibility and outcomes of transcatheter aortic valve implantation in high-risk patients with stenotic bicuspid aortic valves. *Am. J. Cardiol.*, **110**(6):877-883. [doi:10.1016/j.amjcard.2012.04.064]
- Kochman, J., Huczek, Z., Scisło, P., et al., 2014. Comparison of one- and 12-month outcomes of transcatheter aortic valve replacement in patients with severely stenotic bicuspid versus tricuspid aortic valves (results from a multicenter registry). *Am. J. Cardiol.*, **114**(5):757-762. [doi:10.1016/j.amjcard.2014.05.063]
- Leon, M.B., Smith, C.R., Mack, M., et al., 2010. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N. Engl. J. Med.*, **363**(17):1597-1607. [doi:10.1056/NEJMoa1008232]
- Leon, M.B., Piazza, N., Nikolsky, E., et al., 2011. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. *J. Am. Coll. Cardiol.*, **57**(3):253-269. [doi:10.1016/j.jacc.2010.12.005]
- Nistri, S., Basso, C., Marzari, C., et al., 2005. Frequency of bicuspid aortic valve in young male conscripts by echocardiogram. *Am. J. Cardiol.*, **96**(5):718-721. [doi:10.1016/j.amjcard.2005.04.051]
- Roberts, W.C., 1970. The congenitally bicuspid aortic valve: a study of 85 autopsy cases. *Am. J. Cardiol.*, **26**(1):72-83. [doi:10.1016/0002-9149(70)90761-7]
- Roberts, W.C., Ko, J.M., 2005. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. *Circulation*, **111**(7):920-925. [doi:10.1161/01.CIR.000.155623.48408.C5]
- Sievers, H.H., Schmidtke, C., 2007. A classification system for the bicuspid aortic valve from 304 surgical specimens. *J. Thorac. Cardiovasc. Surg.*, **133**(5):1226-1233. [doi:10.1016/j.jtcvs.2007.01.039]
- Smith, C.R., Leon, M.B., Mack, M.J., et al., 2011. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N. Engl. J. Med.*, **364**(23):2187-2198. [doi:10.1056/NEJMoa1103510]
- Tutar, E., Ekici, F., Atalay, S., et al., 2005. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. *Am. Heart J.*, **150**(3):513-515. [doi:10.1016/j.ahj.2004.10.036]
- Wijesinghe, N., Ye, J., Rodés-Cabau, J., et al., 2010. Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis. *JACC Cardiovasc. Interv.*, **3**(11):1122-1125. [doi:10.1016/j.jcin.2010.08.016]
- Zegdi, R., Ciobotaru, V., Noghin, M., et al., 2008. Is it reasonable to treat all calcified stenotic aortic valves with a valved stent? Results from a human anatomic study in adults. *J. Am. Coll. Cardiol.*, **51**(5):579-584. [doi:10.1016/j.jacc.2007.10.023]
- Zegdi, R., Lecuyer, L., Achouh, P., et al., 2010. Increased radial force improves stent deployment in tricuspid but not in bicuspid stenotic native aortic valves. *Ann. Thorac. Surg.*, **89**(3):768-772. [doi:10.1016/j.athoracsur.2009.12.022]

中文概要

题目: 经导管主动脉瓣置入术在中国人群二叶式主动脉瓣重度狭窄中的安全性和有效性评估

目的: 评估经导管主动脉瓣置入术在中国人群二叶式主动脉瓣重度狭窄中的安全性和有效性。

创新点: 首次在中国人群比较经导管主动脉瓣置入术在二叶式和三叶式主动脉瓣重度狭窄中的安全性和有效性。

方法: 选取 2013 年 3 月至 2014 年 9 月行经导管主动脉瓣置入术的 40 位主动脉瓣狭窄的患者, 分二叶式和三叶式主动脉瓣两组, 比较基线水平、手术以及随访 1 月结果的差别。

结论: 经导管主动脉瓣置入术在中国人群中二叶式主动脉瓣重度狭窄中的应用是安全有效的。

关键词: 主动脉瓣狭窄; 二叶式主动脉瓣; 经导管主动脉瓣置入术